11/14
11:13 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
Low
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
11/14
08:15 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
11/13
07:00 am
acrv
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Medium
Report
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
10/17
08:00 am
acrv
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
Medium
Report
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
10/16
04:00 pm
acrv
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11
08:00 am
acrv
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Low
Report
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity